Showing 7,921 - 7,940 results of 29,259 for search '(( 5 ((ng decrease) OR (nn decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 1.01s Refine Results
  1. 7921

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”
  2. 7922

    Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects by Xiaopeng Peng (9136955)

    Published 2022
    “…Importantly, the combination of <b>NT-6</b> with a small-molecule PD-L1 inhibitor NP-19 decreased tumor burden significantly (TGI% = 77.6%). …”
  3. 7923
  4. 7924
  5. 7925
  6. 7926

    Distinct characteristics and outcomes in elderly-onset IgA vasculitis (Henoch-Schönlein purpura) with nephritis: Nationwide cohort study of data from the Japan Renal Biopsy Registr... by Hiroyuki Komatsu (2292505)

    Published 2018
    “…Significantly more elderly than adult patients developed a 50% increase in sCr during a mean observation period of 3.9 years (21.7% vs. 4.7%, p = 0.012), and significantly fewer elderly, than adult patients achieved clinical remission (23.9% vs. 46.2%, p = 0.016). …”
  7. 7927

    Lead Optimization of Androgen Receptor-HSP27 Disrupting Agents in Glioblastoma by Yaxin Li (312731)

    Published 2023
    “…Compounds <b>4</b> and <b>6</b> exhibit IC<sub>50</sub>s of 35 and 23 nM, respectively, to inhibit cell proliferation and also show significant activity to decrease the tumor growth <i>in vivo</i>.…”
  8. 7928
  9. 7929

    DataSheet1_The Variants at APOA1 and APOA4 Contribute to the Susceptibility of Schizophrenia With Inhibiting mRNA Expression in Peripheral Blood Leukocytes.pdf by Yao Fan (1977274)

    Published 2021
    “…After the SZ patients received an average of 27.50 ± 9.90 days of antipsychotic treatment, the median (interquartile) of serum apoA1 in the SZ episode significantly increased from 1.03 (1.00.1.20) g/L to 1.08 (1.00.1.22) g/L with the p-value of 0.044.…”
  10. 7930
  11. 7931
  12. 7932
  13. 7933
  14. 7934
  15. 7935
  16. 7936

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”
  17. 7937

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”
  18. 7938

    Discovery of 2‑Ethoxy-5-isobutyramido‑<i>N</i>‑1-substituted Benzamide Derivatives as Selective Kv2.1 Inhibitors with In Vivo Neuroprotective Effects by Jie Zhou (28945)

    Published 2023
    “…In this work, a series of novel benzamide derivatives were designed and synthesized as Kv2.1 inhibitors, and extensive structure–activity relationships led to highly potent and selective Kv2.1 inhibitors having IC<sub>50</sub> values of 10<sup>–8</sup> M. …”
  19. 7939
  20. 7940